Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 48

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
  
     69,868 

    Operating Expenses: 

    Research and Development 
     407,622  
     337,182 
  
    General and Administrative Expenses 
     1,686,264  
     1,075,134 
  
    Total Operating Expenses 
     2,093,886  
     1,412,316 

    Loss from Operations 
     (1,910,875) 
     (1,342,448)

    Interest Expense 
     (1,790) 
     (1,402)
  
    Change in Fair Value of Derivative Liabilities 
     5,105  
     1,740,847 
  
    Other Income, net 
     30,322  
     31,051 
  
    Total Interest and Other Income, net 
     33,637  
     1,770,496 
  
    (Loss) Income from Operations before Provision for Income Taxes 
     (1,877,238) 
     428,048 
  
    Provision for Income Taxes 
     63  
     63 
  
    Net (Loss) Income including Noncontrolling Interest 
     (1,877,301) 
     427,985 
  
    Net Loss – Noncontrolling Interest 
     (752) 
     (2,485)
  
    Net (Loss) Income – attributed to 60 Degrees Pharmaceuticals, Inc. 
    $(1,876,549) 
    $430,470 

The following table sets forth our results of
operations as a percentage of revenue:

    For the Three Months Ended March 31, 
  
    Consolidated Statements of Operations Data: 
    2025  
    2024 
  
    Product Revenues – net of Discounts and Rebates 
     100.00% 
     100.00%
  
    Cost of Revenues 
     44.80  
     61.92 
  
    Gross Profit 
     55.20  
     38.08 
  
    Research Revenues 
     56.70  
     28.04 
  
    Net Revenue 
     111.90  
     66.12 

    Operating Expenses: 

    Research and Development 
     249.23  
     319.08 
  
    General and Administrative Expenses 
     1